# Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

Study · id `cardio:ct-nct03775746` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03775746](<https://clinicaltrials.gov/study/NCT03775746>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03775746

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT03775746. Randomized; no masking; primary purpose treatment. Start 2019-01-08 (actual); primary completion 2021-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT03775746, source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)
- Started: 2019-01-08 (actual) (ClinicalTrials.gov record NCT03775746, source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)
- Primary completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03775746, source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03775746, source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03775746, source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03775746-2020-02-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
- Acronym: VaLiDate-R
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Clopidogrel 75Mg Tablet
- Intervention (Drug): Rivaroxaban 2.5Mg Tablet
- Intervention (Drug): Ticagrelor 90Mg Tablet
- Lead sponsor: East and North Hertfordshire NHS Trust
- Lead sponsor class: OTHER\_GOV
- Collaborator: University of Hertfordshire
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

## Provenance

Content hash: 3323d7a9c220446786276d5e635dc56ff0d75a296181af6344048b6fc2fbe6e4
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
